President Donald Trump’s choice of Dr. Heidi Overton to lead the Food and Drug Administration faced Republican resistance Wednesday as Senate Health Committee Chair Bill Cassidy (R-La.) said her role in the administration’s vaccine order was "almost disqualifying."
Cassidy Raises Concerns Over Overton Nomination
"While I respect Dr. Overton’s experience as a physician, I have strong concerns about her nomination to be FDA Commissioner," Cassidy wrote on X. His committee will oversee Overton’s confirmation. Trump formally announced Overton as his FDA pick Wednesday.
While I respect Dr. Overton’s experience as a physician, I have strong concerns about her nomination to be FDA Commissioner. Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues.…
— U.S. Senator Bill Cassidy, M.D. (@SenBillCassidy) August 19, 2026
Cassidy said Overton’s "lack of managerial experience" does not prepare her to run an agency facing staffing and morale problems. He also attacked her "active role in last week’s nonsensical vaccine executive order," saying it raises doubts about her commitment to "sound science and protecting children’s health."
"That alone is almost disqualifying," Cassidy added.
Vaccine Order Could Shape Confirmation Fight
Trump called the White House deputy domestic policy director a "rockstar" and said, "We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES." AP notes Overton has become a trusted administration health-policy figure and supporter of Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again agenda.
The dispute centers partly on Trump’s Aug. 10 order seeking to separate the combined measles, mumps and rubella vaccine into three shots, contrary to recommendations from medical groups. Overton stood beside Trump at the Oval Office event. AP noted decades of evidence show no link between vaccines and autism. The broader debate over splitting the combined MMR vaccine had already drawn opposition from Merck and medical experts.
Overton Would Inherit Troubled FDA
Overton would inherit an FDA recovering from the loss of more than 3,000 employees and leadership turnover. Reuters reported that drugmakers and agency employees have questioned whether her management background is sufficient for an organization destabilized by layoffs and senior exits.
That turmoil predates her nomination. Earlier reporting detailed White House plans to remove Marty Makary before he resigned in May, while acting drug-center chief Tracey Beth Hoeg was fired days later and said the order came from "way above."
Overton previously served as chief policy officer at the America First Policy Institute and trained at Johns Hopkins, where she overlapped with Makary. If confirmed, she would become the latest physician to lead the FDA.
Photo courtesy: Shutterstock
